Cardiology · Cardiomyopathies
Cardiac Amyloidosis
ATTR-CM · AL Amyloidosis · Tafamidis · Nuclear Scintigraphy
Amyloid fibrils — misfolded proteins rearranged into insoluble beta-pleated sheets — deposit in the extracellular space of the myocardium and produce a restrictive cardiomyopathy that masquerades for years as hypertensive heart disease, hypertrophic cardiomyopathy, or simply the expected deterioration of an aging heart. Two forms account for virtually all clinically significant cardiac amyloidosis. Transthyretin amyloidosis (ATTR-CM) arises when the liver's transport protein transthyretin either dissociates spontaneously with aging (wild-type, wt-ATTR) or dissociates prematurely due to one of over 130 point mutations in the TTR gene (hereditary variant, hATTR). Light-chain amyloidosis (AL-CM) arises from a clonal plasma cell disorder in which immunoglobulin light chains detach, misfold, and accumulate in cardiac tissue.[1] In both forms, amyloid infiltration stiffens the ventricle, impairs relaxation, and raises filling pressures — producing heart failure with preserved ejection fraction (HFpEF) while the systolic function appears deceptively normal. The stroke volume is fixed, cardiac output is maintained by heart rate, and the medications most often prescribed for HFpEF — beta-blockers, calcium channel blockers, and ACE inhibitors — become weapons against the patient. Until 2018, no disease-modifying therapy existed and the diagnosis was academic. The ATTR-ACT trial changed that: tafamidis, a small-molecule TTR stabilizer, reduced all-cause mortality by 30% and cardiovascular hospitalizations by 32% compared to placebo in patients with ATTR-CM.[9] The disease that spent a century hiding behind other diagnoses now has a treatment — but only if it is found.
In 1842, the Viennese pathologist Carl von Rokitansky described peculiar white, waxy deposits in the enlarged hearts and livers of patients who had died after prolonged illness — he called it "lardaceous degeneration" because the affected organs resembled bacon.[1] A decade later, Rudolf Virchow examined these deposits more carefully. When he stained them with iodine and sulfuric acid, the reaction turned blue, suggesting they were starch-like; he coined the word amyloid from amylum, the Latin word for starch. He was wrong about the chemistry — Carl Freidreich would later demonstrate that amyloid was not starch but closer to a protein — but the name stuck. The conceptual confusion about what amyloid actually was persisted for decades, and that confusion had clinical consequences: the disease it caused was attributed to everything except what it actually was.
The diagnostic breakthrough came from histochemistry, not clinical observation. The introduction of Congo red staining in the early twentieth century revealed that amyloid deposits, under polarized light, displayed a distinctive apple-green birefringence — a finding tied to the beta-pleated sheet secondary structure common to all amyloid fibrils regardless of their protein of origin. This remains the pathologic gold standard today. What took longer to understand was the biochemical diversity of amyloidosis: at least 30 different precursor proteins can misfold into amyloid fibrils, each with its own organ tropism, clinical presentation, and treatment implications. The failure to classify amyloidosis by protein subtype — rather than by appearance alone — meant that for most of the twentieth century, physicians lumped together diseases that were in fact entirely distinct in mechanism and required entirely different therapies.
The clinical consequences of that failure were severe. Cardiac amyloidosis spent decades hiding behind two diagnoses that were more familiar to the physicians who were looking at the same echocardiograms: hypertensive heart disease and hypertrophic cardiomyopathy. Both produce left ventricular wall thickening. Both can present with HFpEF. But in cardiac amyloidosis, the thickening is extracellular amyloid infiltration rather than myocyte hypertrophy — and the treatments for hypertensive LVH are, in many cases, acutely dangerous in amyloidosis. Meanwhile, the clues were present in the history: carpal tunnel syndrome frequently predates the cardiac diagnosis of amyloidosis by five to ten years, and a 2018 study found that 10.2% of patients undergoing surgical carpal tunnel release had amyloid deposits in the tenosynovial tissue on biopsy.[1] The carpal tunnel surgeon and the hand surgeon were seeing these patients long before the cardiologist did — and the cardiologist was not asking about carpal tunnel.
The therapeutic era began with the ATTR-ACT trial, published in the New England Journal of Medicine in 2018. Tafamidis, a small-molecule stabilizer that binds to the thyroxine-binding site on the transthyretin tetramer and prevents its dissociation into amyloidogenic monomers, was randomized against placebo in 441 patients with wtATTR and vATTR cardiomyopathy. The result was unambiguous: a 30% reduction in all-cause mortality and a 32% reduction in cardiovascular hospitalizations, with slower decline in functional capacity and quality of life.[9] The FDA approved tafamidis for ATTR-CM in 2019. For the first time, a disease-modifying therapy existed for a cardiomyopathy caused not by a problem within the myocyte itself but by a misfolded protein arriving from the liver. The implication was clear: making the diagnosis matters, because now something can be done about it.
Transthyretin is a tetrameric transport protein synthesized almost entirely in the liver. It carries less than 5% of circulating thyroxine and is the primary transporter of retinol-binding protein. Under normal conditions, the four identical monomers assemble into a tightly folded tetramer that is thermodynamically stable. In wild-type ATTR amyloidosis, aging itself causes the tetramer to lose kinetic stability — the monomers dissociate, misfold into beta-sheet-rich conformations, and aggregate into insoluble amyloid fibrils that deposit preferentially in the heart, the tenosynovial tissue of the carpal tunnel, the ligamentum flavum of the lumbar spine, and the biceps tendon. In hereditary ATTR amyloidosis, point mutations in the TTR gene on chromosome 18 create a structurally unstable tetramer that dissociates and misfolds earlier in life, at lower temperatures, and in smaller amounts of protein.[1] The most clinically important mutation in the United States is p.V142I (historically called Val122Ile), which is found in 3.4% of Black Americans and leads to predominantly cardiac disease with onset typically in the sixth decade. Over 130 pathogenic mutations have been described, each with a distinct geographic distribution, organ phenotype, and age of onset.
AL amyloidosis arises from a completely different mechanism. A clonal population of plasma cells in the bone marrow produces immunoglobulins with an intrinsically unstable light-chain domain. The light chain detaches from the heavy chain, escapes into the circulation, misfolds, and deposits in target organs as amyloid fibrils. The heart is affected in 50–75% of AL amyloidosis cases; over 70% of cardiac AL amyloidosis is lambda-associated, reflecting a unique predisposition of lambda light chains to deposit in cardiac tissue. Unlike ATTR amyloidosis, in which the protein causing the damage is produced by the liver and is theoretically addressable without destroying the organ producing it, the problem in AL is the plasma cell itself — and eliminating the plasma cell requires hematologic treatment with chemotherapy or targeted biologics.[1]
The hemodynamic consequence of amyloid infiltration is identical regardless of protein subtype: extracellular amyloid deposits in the myocardium reduce compliance, impair diastolic relaxation, and raise left ventricular filling pressures. The result is a restrictive cardiomyopathy with a small, non-compliant ventricle, elevated atrial pressures, and the clinical syndrome of HFpEF. Left ventricular ejection fraction is typically preserved or only mildly reduced, but stroke volume index is frequently reduced because the small, stiff ventricle cannot fill adequately. This creates a critical physiologic constraint: cardiac output equals heart rate times stroke volume, and in cardiac amyloidosis stroke volume is fixed. Patients depend on an elevated heart rate to maintain an adequate cardiac output at rest and with exertion. When a physician prescribes a beta-blocker for rate control — a standard reflex in any patient with HFpEF and rapid heart rate — the resulting bradycardia in a patient with fixed stroke volume can precipitate acute hemodynamic decompensation. The same logic applies, more severely, to non-dihydropyridine calcium channel blockers: verapamil has been associated with cardiogenic shock in AL amyloidosis through a combination of negative inotropy and heart rate reduction.[5]
The autonomic nervous system is a frequent casualty of systemic amyloidosis, particularly in AL and vATTR disease. Amyloid deposits in autonomic ganglia and peripheral nerve fibers disrupt the normal vasoconstrictor reflex that maintains blood pressure during positional changes. The clinical consequence is orthostatic hypotension that is paradoxically worsened by medications intended to treat the underlying condition: ACE inhibitors and angiotensin receptor blockers lower blood pressure in the setting of impaired compensatory vasoconstriction, leading to symptomatic syncope and falls. This autonomic neuropathy also blunts the normal heart rate response to exertion and physiologic stress, limiting the principal compensatory mechanism available to the amyloid heart. Arrhythmias are common in all forms of cardiac amyloidosis. Atrial fibrillation prevalence increases with disease duration, with some series reporting AF in over 50% of patients with advanced disease. The mechanisms include biatrial enlargement from elevated filling pressures, direct amyloid infiltration of the atrial myocardium, and autonomic dysfunction. Importantly, patients with cardiac amyloidosis are particularly prone to intracardiac thrombus formation even in sinus rhythm — endomyocardial amyloid deposition impairs atrial contractile function independent of the underlying rhythm, justifying anticoagulation regardless of CHA₂DS₂-VASc score in any amyloid patient with AF.
The distinction between ATTR and AL amyloidosis is not academic — it determines the diagnostic strategy, the treatment, and the prognosis. The first and most important step in any patient with suspected cardiac amyloidosis is to exclude AL with immunoglobulin studies before proceeding to nuclear scintigraphy. A positive Tc99m-PYP scan in the setting of an undetected monoclonal protein is a false-positive waiting to happen.[6]
| Subtype | Epidemiology | Presentation | Diagnosis | Prognosis (untreated) | Treatment |
|---|---|---|---|---|---|
| wt-ATTR Wild-type transthyretin |
Age >70; predominantly Caucasian men (>90%); found in 25% of autopsies age >80; formerly called "senile cardiac amyloidosis" | HFpEF; concentric LVH; carpal tunnel syndrome; spinal stenosis; biceps tendon rupture; peripheral neuropathy uncommon | Tc99m-PYP grade 2–3 + no monoclonal protein → non-biopsy ATTR-CM diagnosis; genetic testing shows no TTR mutation (confirms wt) | Median 3.6 yrs; Stage 1/2/3: 66/42/20 months | Tafamidis 80 mg daily (FDA approved) |
| hATTR V142I p.V142I mutation |
3.4% of Black Americans; also West African and African Caribbean descent; onset 60s; most common pathogenic ATTR mutation in the US | Predominantly cardiac HFpEF; carpal tunnel common; peripheral sensorimotor neuropathy rare; ~25% of ATTR-CM in Black Americans is actually wt-ATTR (not V142I) | Tc99m-PYP scan + TTR genetic testing confirms p.V142I; cascade screening of first-degree family members | Median 2.5 yrs | Tafamidis 80 mg daily; patisiran or inotersen if concomitant neuropathy |
| hATTR V30M & others >130 pathogenic mutations |
V30M endemic in Portugal/Japan/Sweden (early onset neuropathy); late-onset V30M in US has mixed cardiac/neuropathy phenotype; Thr60Ala in Irish Americans (Donegal); Ile68Leu from Italy | Mixed neuropathy + cardiomyopathy (phenotype varies by mutation); autonomic dysfunction often precedes cardiac symptoms; carpal tunnel common | Tc99m-PYP scan + genetic testing identifying specific mutation | Variable by mutation | Tafamidis; patisiran or inotersen for neuropathy component |
| AL Amyloidosis Light-chain (plasma cell dyscrasia) |
10 per million per year incidence; age >50; affects heart in 50–75%; lambda light chains more than kappa (70% of cardiac AL is lambda); can arise from multiple myeloma (>20% BM plasma cells) or monoclonal gammopathy | HFpEF; renal disease (nephrotic-range proteinuria in 60%); periorbital purpura; macroglossia; dental indentations on tongue (15%); autonomic neuropathy (15%); pleural effusions; diarrhea | Serum FLC assay + serum/urine immunofixation (NOT SPEP alone — too insensitive); → fat pad + bone marrow biopsy confirms 85%; Congo red staining; mass spectrometry for subtyping | Median 1.5 yrs; Stage 1/2/3/4: 73/35/15/5 months | Daratumumab + CyBorD (hematology-led); stem cell transplant in selected patients |
Any patient who presents with HFpEF plus two or more of the following should be screened immediately for cardiac amyloidosis before initiating standard HFpEF therapy: (1) carpal tunnel syndrome, bilateral or recurrent; (2) peripheral or autonomic neuropathy; (3) LV wall thickness >1.2 cm with "low-voltage discordance" — voltage on ECG lower than expected for wall thickness; (4) aortic stenosis, particularly low-flow low-gradient in an elderly patient; (5) spinal stenosis or biceps tendon rupture; (6) inability to tolerate standard heart failure medications at typical doses (ACEi, ARB, or beta-blocker causing hypotension or syncope). These are not coincidences — they are a phenotype.
Drug hazards unique to amyloidosis: Non-dihydropyridine calcium channel blockers (verapamil, diltiazem) are associated with cardiogenic shock in AL amyloidosis — avoid them. ACE inhibitors and ARBs cause symptomatic orthostatic hypotension in patients with autonomic neuropathy (vATTR and AL) — use with extreme caution. Beta-blockers, if given for rate control, must be used at the lowest possible dose: a fixed stroke volume depends on an elevated heart rate to maintain cardiac output, and standard beta-blocker doses can precipitate acute hemodynamic collapse. Regarding digoxin: the traditional teaching holds that digoxin binds to amyloid fibrils in the myocardium, increasing effective drug concentrations and risk of toxicity. While a 2020 retrospective study (Donnelly et al.) suggested digoxin can be used carefully in selected patients, the margin for error is narrow. If used at all for AF rate control, the lowest possible dose with close monitoring is required.
The bedside examination in cardiac amyloidosis rarely makes the diagnosis — it can suggest the diagnosis, and that suggestion is the only thing that matters in a disease where the clinician who does not look never finds. The classic ECG finding of low voltage is present in fewer than 40% of patients; its absence does not exclude amyloidosis. The more diagnostically meaningful ECG finding is a discordance between LV wall thickness on echocardiogram and voltage on ECG: a patient whose walls measure 1.5 cm on echo but whose QRS voltage is unexpectedly low for that degree of thickening should raise immediate suspicion.[1] A pseudo-infarct pattern — Q waves in precordial or inferior leads without a history of myocardial infarction — is another electrocardiographic clue to amyloid infiltration that disrupts normal conduction through the myocardium.
| Finding | Sensitivity | Specificity | Clinical Pearl |
|---|---|---|---|
| Concentric LVH ≥1.2 cm on echo | High for screening | Low | Also seen in HTN, HCM, ESRD, Fabry disease; thickening in amyloidosis is extracellular infiltration, not myocyte hypertrophy — subtle but important pathologic distinction |
| Granular "sparkling" echo texture | ~60% | Low | Classic teaching but less useful in modern harmonic imaging, which makes many pathologic myocardiums appear bright; do not rely on this sign alone |
| Low-voltage ECG (<5 mm in limb leads) | <40% | Moderate | Absence of low voltage does NOT exclude amyloidosis; voltage-wall thickness discordance is more reliable than low voltage alone |
| Pseudo-infarct pattern on ECG | ~47% | Moderate–High | Pathologic Q waves in absence of prior MI or CAD; amyloid disrupts conduction through infiltrated myocardium; check for posterior and inferior leads |
| Apical sparing on GLS ("cherry-on-top") | ~79% | ~83% | Base/mid longitudinal strain reduced with relative preservation of apical strain; distinguishes amyloidosis from HCM (septal-predominant) — most useful echocardiographic discriminator available on standard echo |
| Grade 2–3 Tc99m-PYP uptake + no M-protein | >99% | ~100% | Specificity approaches 100% when monoclonal protein is excluded; confirm with SPECT to differentiate myocardial uptake from blood pool; a positive PYP without SPECT confirmation is an incomplete study |
| Elevated serum free light chain ratio | High for AL screening | Moderate | FLC assay is more sensitive than SPEP for detecting AL amyloidosis; an abnormal FLC ratio (<0.26 or >1.65) with or without a detectable M-protein triggers referral to hematology and tissue biopsy |
Point-of-care ultrasound cannot diagnose cardiac amyloidosis — that requires nuclear scintigraphy, serum markers, and often tissue. What POCUS can do is shorten the distance between clinical suspicion and appropriate workup: the bedside echo that shows thick walls, granular texture, restricted diastology, biatrial enlargement, and apical sparing on visual assessment is the echo that generates the referral for Tc99m-PYP scintigraphy. The clinician who knows what to look for will find it; the one who does not is staring at the answer without recognizing the question.[8]
Pearl 1 — Concentric LVH on Parasternal Long Axis. Acquire the PLAX view with the probe at the 3rd–4th left intercostal space, marker toward the patient's right shoulder, marker displayed on the right of the screen. Measure the posterior wall and interventricular septal thickness in diastole. Walls ≥1.2 cm in the setting of HFpEF without longstanding hypertension or outflow obstruction should prompt systematic evaluation for amyloidosis. A key conceptual point: amyloid LVH looks similar to hypertensive LVH on 2D imaging, but the mechanisms differ fundamentally. Hypertensive LVH is myocyte hypertrophy — cells getting bigger. Amyloid LVH is extracellular infiltration — cells being pushed apart by deposited protein. The myocytes themselves are being compressed, not enlarged, which is why systolic dysfunction and reduced GLS emerge even while EF appears preserved.[8]
Pearl 2 — Granular "Sparkling" Texture and Right Ventricular Hypertrophy. The classic "granular sparkling" echo texture of amyloid-infiltrated myocardium reflects the scattering of ultrasound by extracellular amyloid deposits. In the era of harmonic imaging, this sign has lower specificity than historically taught — the myocardium can appear bright in ESRD, Fabry disease, and hypertensive LVH as well. More specific is the finding of right ventricular wall thickening alongside LV thickening: amyloid deposits in both ventricles simultaneously, while most forms of LVH are predominantly left-sided. Biatrial enlargement on the A4C view (both atria enlarged, often out of proportion to ventricular size) adds further specificity. A small pericardial effusion is present in up to 25% of patients with advanced disease and, in the context of thick walls and HFpEF, should heighten suspicion for amyloidosis.[8]
Pearl 3 — Restrictive Diastology on Mitral Inflow. Place the pulsed-wave Doppler sample volume at the mitral valve tips on the A4C view. In early amyloidosis, impaired relaxation produces an E/A ratio <1. As the disease progresses and filling pressures rise, the pattern evolves through pseudonormalization to frank restriction: E/A >2, E deceleration time <150 ms. Tissue Doppler imaging of the mitral annulus (lateral e') reveals a blunted e' velocity — often <7 cm/s — despite the elevated E velocity, giving a very high E/e' ratio (>15, frequently >20) that reflects severely elevated LV filling pressures. This pattern of restrictive diastology in the setting of a thick-walled, non-dilated LV is the hemodynamic fingerprint of cardiac amyloidosis and should trigger immediate workup regardless of preserved EF.[8]
Pearl 4 — Apical Sparing on Global Longitudinal Strain. Global longitudinal strain (GLS) assessment by speckle-tracking echocardiography reveals one of the most diagnostically specific patterns in all of cardiac imaging: relative apical sparing, or the "cherry-on-top" pattern. Strain is markedly reduced in the basal and mid segments of the LV (reflecting high amyloid burden at the base) but is relatively preserved at the apex (where amyloid burden is lower). The resulting bull's-eye plot shows the apex lit up in orange-red while the base and mid segments remain dark — a pattern both sensitive (~79%) and specific (~83%) for cardiac amyloidosis and validated against histologic burden.[7] This contrasts with HCM, where GLS reduction is concentrated in the hypertrophied septum, and with hypertensive LVH, where strain reduction is more diffuse and less severe. Visual assessment for apical sparing during bedside POCUS — scanning the apical views for relative preservation of apical wall motion compared to the base — provides a high-yield qualitative clue without requiring dedicated strain software.[8]
Pearl 5 — IVC Assessment in the Amyloid Patient. On the subcostal view, the IVC in advanced cardiac amyloidosis is often plethoric and non-collapsing, reflecting chronically elevated right atrial pressure from the restrictive physiology. A plethoric IVC (>2.1 cm with <50% collapse) in a patient with HFpEF and thick walls should prompt consideration of amyloidosis as a cause of the right-sided pressure elevation, rather than assuming pulmonary hypertension or right heart failure from another cause. Volume management in amyloidosis is narrow: the stiff ventricle requires adequate preload, but excessive diuresis removes the filling pressure needed to maintain stroke volume.
The diagnostic algorithm for cardiac amyloidosis is sequential and branching: the first question asked determines which test comes next. Every patient with unexplained LVH, HFpEF with walls ≥1.2 cm, or the amyloidosis phenotype cluster must be evaluated for AL disease first with serum markers — before nuclear scintigraphy is ordered. An elevated monoclonal protein or free light chain ratio in a patient with a positive nuclear scan does not confirm ATTR; it mandates tissue biopsy to determine whether the nuclear positivity represents AL (which can produce false-positive Tc99m-PYP results in up to 21% of cardiac AL cases) or coincident ATTR amyloidosis.[6]
| Test | Clinical Rationale |
|---|---|
| Serum free light chain (FLC) assay | First-line screen for AL — do not substitute SPEP. An abnormal kappa/lambda FLC ratio (<0.26 or >1.65) is the most sensitive serologic screen for AL amyloidosis. SPEP and UPEP alone are insufficiently sensitive to exclude AL disease and should not be used without immunofixation. Order FLC assay + serum immunofixation electrophoresis (SIFE) + urine immunofixation electrophoresis (UIFE) simultaneously for maximum sensitivity. |
| Serum and urine immunofixation electrophoresis (SIFE/UIFE) | Detects monoclonal protein (M-protein) missed by SPEP; any detected M-protein triggers referral to hematology/oncology for evaluation of AL amyloidosis. Even a small M-protein that would otherwise be monitored as MGUS requires exclusion of AL in the context of clinical amyloidosis suspicion. |
| NT-proBNP and high-sensitivity troponin T | Mayo staging (wt-ATTR): NT-proBNP >3000 pg/mL = 1 point; TnT >0.05 ng/mL = 1 point. Stage 1 (0 pts): 66 months median survival. Stage 2 (1 pt): 42 months. Stage 3 (2 pts): 20 months. In AL, staging uses NT-proBNP ≥1800 pg/mL, TnT >0.025 ng/mL, and light-chain difference >180 mg/L — Stage 4 AL (all three abnormal) has a median survival of only 5 months. |
| Tc99m-PYP scintigraphy with SPECT | Non-biopsy diagnosis of ATTR-CM (US uses PYP; Europe uses DPD or HMDP). Grade 2 or 3 uptake on planar images + no detectable monoclonal protein confirms ATTR-CM with specificity approaching 100%.[6] Must be confirmed with SPECT to exclude blood pool signal — planar imaging alone without SPECT is inadequate. Sensitivity >99% for ATTR cardiac involvement. Quantitative heart-to-contralateral lung ratio >1.5 at 1 hour is an alternative diagnostic threshold. After a positive scan, genetic testing discriminates wt-ATTR from vATTR. |
| TTR gene sequencing (genetic testing) | Mandatory in all patients with confirmed or suspected ATTR amyloidosis; identifies the specific pathogenic variant (if any); has direct implications for choice of therapy (patisiran/inotersen approved only for hATTR with neuropathy), eligibility for clinical trials, and cascade screening of first-degree family members regardless of patient age. |
| Cardiac MRI with gadolinium (CMR) | Diffuse subendocardial LGE progressing to transmural in advanced disease; inability to null the myocardium with standard inversion recovery sequences; markedly elevated extracellular volume (ECV >0.5 on T1 mapping) — most reproducible MRI measure of amyloid burden. CMR does not distinguish AL from ATTR and cannot independently diagnose or justify treatment. Late gadolinium enhancement is a strong predictor of mortality across all amyloid subtypes. |
| Fat pad and/or bone marrow biopsy | When AL is suspected: fat pad + bone marrow biopsy together confirm AL amyloidosis histologically in 85% of cases via Congo red staining + mass spectrometry. Bone marrow biopsy also excludes multiple myeloma (plasma cells >20%) and identifies cytogenetic markers (t11;14, del17p) that affect chemotherapy response. Fat pad biopsy sensitivity for ATTR is only 45% (vATTR) and 15% (wt-ATTR) — do not use fat pad biopsy to screen for ATTR. |
| Endomyocardial biopsy (EMB) | Gold standard: positive Congo red birefringence + mass spectrometric protein subunit typing confirms amyloid type with 90% accuracy. Reserved for: (1) cases where nuclear scan and biopsy are inconclusive but clinical suspicion remains high; (2) patients with a monoclonal protein and positive nuclear scan who require definitive subtyping; (3) any case where treatment decisions depend on tissue confirmation. |
Treatment strategy in cardiac amyloidosis is determined entirely by amyloid subtype — which is why getting the diagnosis right is not optional. Tafamidis treats ATTR-CM; daratumumab-based chemotherapy treats AL; giving the wrong treatment for the wrong subtype is not merely ineffective, it is dangerous. In ATTR-CM, the therapeutic target is the protein's source — the liver — not the heart itself. In AL, the therapeutic target is the plasma cell clone producing the pathologic light chain. Symptomatic management (diuretics, arrhythmia management, device therapy) applies to both, within the pharmacologic constraints imposed by the disease's hemodynamic peculiarities.[1]
| Intervention | When & How | Evidence & Key Points |
|---|---|---|
| Tafamidis 80 mg daily (Vyndamax) | FDA-approved for ATTR-CM (both wt-ATTR and vATTR). Oral once daily. No dose adjustments for age, renal function, or hepatic impairment. Mechanism: binds thyroxine-binding sites on TTR tetramer, stabilizing it against dissociation and misfolding. | ATTR-ACT (NEJM 2018)[9]: win ratio 1.70 (p=0.0006) for composite all-cause mortality + CV hospitalizations. 30% reduction in all-cause mortality hazard; 32% reduction in CV hospitalization hazard. Slower decline in 6-minute walk test and KCCQ scores. The only FDA-approved disease-modifying therapy for ATTR-CM in the United States. |
| Acoramidis (ATTRibute-CM) | Second-generation TTR stabilizer; near-complete TTR stabilization in Phase 2 studies. Part B of Phase 3 ATTRibute-CM trial (hierarchal endpoint including all-cause mortality, CV hospitalizations, and 6MWT at 30 months) results pending. Not yet FDA-approved for ATTR-CM. | Phase 3 Part A: no difference in 6-minute walk distance at 12 months vs. placebo (primary endpoint not met). Open-label extension from Phase 2 showed lower mortality/CV hospitalizations at 15 months. More affordable than tafamidis if approved. FDA approval status pending Part B results. |
| Diflunisal 250 mg BID | Off-label use of an NSAID that also stabilizes the TTR tetramer. More affordable alternative to tafamidis. Not FDA-approved for amyloidosis. Monitor GFR and GI symptoms. Avoid in advanced CKD. | Single-center data only; no randomized trial data for ATTR-CM. Associated with small reduction in eGFR and slightly increased GI complaints. Response monitored by serum prealbumin (TTR) levels. Consider in ATTR-CM patients unable to access tafamidis. |
| Patisiran IV q3 weeks (APOLLO) | RNAi therapeutic: intravenously administered siRNA that targets TTR mRNA for hepatic degradation, reducing circulating TTR by >80%. Currently FDA-approved for hATTR polyneuropathy (with or without cardiomyopathy). Investigational for wt-ATTR-CM (APOLLO-B trial: improvement in 6MWT at 12 months). | APOLLO trial (NEJM 2018)[10]: significant improvement in neuropathy scores vs. placebo. Cardiac substudy[12]: less GLS deterioration, regression of LV wall thickness, reduction in NT-proBNP among hATTR patients with concomitant cardiomyopathy. APOLLO-B (ATTR-CM): 12-month improvement in 6MWT vs. placebo (statistically significant). |
| Inotersen SQ weekly | Antisense oligonucleotide that binds TTR mRNA, reducing hepatic TTR production. FDA-approved for hATTR polyneuropathy. Monitor CBC and creatinine weekly: rare but fatal thrombocytopenia (intracranial hemorrhage) and glomerulonephritis require vigilant platelet monitoring. | NEURO-TTR study (NEJM 2018): improved neuropathy scores vs. placebo. Limited cardiac data suggest stabilization of GLS and 6MWT in ATTR patients with cardiomyopathy. Not FDA-approved for ATTR-CM; potential use limited to hATTR patients with neuropathy who also have cardiomyopathy. |
| Daratumumab + CyBorD (ANDROMEDA) | Newly diagnosed AL amyloidosis: daratumumab (anti-CD38 monoclonal antibody) added to cyclophosphamide, bortezomib, and dexamethasone (CyBorD). Hematology-led treatment. Daratumumab now standard of care when available for newly diagnosed AL. | ANDROMEDA (NEJM 2021)[11]: complete hematologic response 53.3% vs 18.1% for CyBorD alone. Cardiac response (≥30% NT-proBNP reduction) 41.5% vs 22.2%. Daratumumab+CyBorD is now the preferred first-line regimen for newly diagnosed AL amyloidosis at most centers. |
| Bortezomib-based chemotherapy (CyBorD) | For AL amyloidosis when daratumumab unavailable or in combination with daratumumab. Bortezomib administered SQ once weekly (reduces neuropathy vs IV). Monitor for peripheral neuropathy, thrombocytopenia, and hypotension. | Hematologic response rate 60–77% with CyBorD; complete response 16% as single agent. In selected eligible patients, autologous stem cell transplantation can achieve durable complete responses (10-year survival 25%; 53% in patients achieving complete response). Transplant-related mortality ~2.5% at experienced centers. |
| Loop diuretics for congestion | Torsemide or bumetanide preferred over furosemide (higher oral bioavailability — critical in patients with bowel wall edema from AL amyloidosis). High-dose aldosterone antagonists can be added for volume management. Titrate carefully: excessive diuresis reduces preload in a ventricle that depends on adequate filling pressure for stroke volume. | Cornerstone of symptomatic management. No goal-directed medical therapy for ATTR-CM exists analogous to GDMT for HFrEF. Diuretics treat symptoms; only tafamidis (ATTR-CM) or chemotherapy (AL) treats the underlying disease. RAAS inhibitors, beta-blockers at standard doses, and non-DHP CCBs are not used for their HFpEF indications — they are either ineffective or actively dangerous in amyloidosis. |
| Anticoagulation in amyloid + AF | Anticoagulate all patients with cardiac amyloidosis and AF regardless of CHA₂DS₂-VASc score. DOACs or warfarin both acceptable. Anticoagulation threshold in amyloidosis is not score-based — the structural abnormality (atrial amyloid infiltration, impaired appendage contractility even in sinus rhythm) justifies anticoagulation at any calculated risk score. | Intracardiac thrombus formation occurs in sinus rhythm in amyloidosis — the LAA does not contract normally even when the rhythm is normal, due to amyloid infiltration of atrial muscle. This justifies a lower threshold for anticoagulation than in AF from other causes. |
| Pacemaker / device therapy | Heart block from conduction system infiltration: pacemaker per ACC/AHA/HRS guidelines. Prefer biventricular pacing in patients with cardiac amyloidosis who require pacing >40% of the time — chronic RV pacing at high burden worsens LV function and MR. ICD for secondary prevention of VT/VF in selected patients with estimated survival >1 year. | Primary prevention ICD data are controversial in amyloidosis. Death in AL amyloidosis frequently results from electromechanical dissociation rather than ventricular arrhythmia — ICD cannot prevent this. Retrospective data show increased LV dysfunction and MR with RV pacing >40%; biventricular pacing may mitigate this in eligible patients. |
| Recommendation — AHA Scientific Statement on Cardiac Amyloidosis (Kittleson MM et al., Circulation 2020)[2] | Class | Level of Evidence |
|---|---|---|
| Serum FLC assay + serum and urine immunofixation electrophoresis in all patients with suspected cardiac amyloidosis before nuclear scintigraphy | I | B |
| Tc99m-labeled bone-avid tracer scintigraphy with SPECT confirmation for non-biopsy diagnosis of ATTR-CM in absence of monoclonal protein | I | B |
| TTR genetic testing in all patients with confirmed or suspected ATTR amyloidosis regardless of age | I | B |
| Tafamidis to reduce mortality and cardiovascular hospitalizations in patients with ATTR-CM (both wt-ATTR and vATTR) | I | B-R |
| Anticoagulation in patients with cardiac amyloidosis and atrial fibrillation, regardless of CHA₂DS₂-VASc score | I | B |
| Referral to hematology/oncology for all patients with suspected AL amyloidosis based on abnormal FLC ratio or M-protein detection | I | B |
| Avoidance of non-dihydropyridine calcium channel blockers in patients with AL amyloidosis | III: Harm | C |
| Loop diuretics (torsemide or bumetanide preferred) for management of congestion in cardiac amyloidosis | IIa | C |
| Cascade genetic testing of first-degree relatives of patients with pathogenic TTR variants | I | B |
There is a diagnostic puzzle at the center of cardiac amyloidosis that rewards careful thinking: the heart that looks thick on echocardiogram and behaves as though it is thin. Stroke volume is low. Ejection fraction is preserved. Voltage on ECG is disproportionately low for the wall thickness. The QRS is small; the walls are thick; the patient cannot tolerate the medications prescribed for the disease the cardiologist thinks they have. This is not a subtle presentation — it is a presentation that announces its own diagnosis, if the physician asking the question knows what the answer looks like.
The reason so many cases were missed for so long has nothing to do with diagnostic technology. The echocardiogram was present. The ECG was present. What was absent was the clinical framework to interpret them correctly. The default explanation for LVH in an elderly patient is hypertension — and in most cases, that explanation is right. But hypertensive LVH produces myocyte hypertrophy, not extracellular infiltration; hypertensive hearts tolerate beta-blockers; hypertensive hearts do not produce the voltage-wall thickness discordance that is one of the most reliable signs in cardiology once recognized. The physician who does not ask "why is the voltage low for this wall thickness?" will prescribe a beta-blocker, lower the heart rate, reduce the cardiac output, and conclude the patient has refractory HFpEF. The physician who does ask the question will order a Tc99m-PYP scan and, in many cases, change the patient's prognosis entirely.[5]
The revolution in non-biopsy diagnosis is worth understanding precisely. The 2016 Gillmore et al. study in Circulation established the diagnostic algorithm that made cardiac amyloidosis diagnosable without a biopsy in most ATTR cases.[6] A grade 2 or 3 uptake on Tc99m-PYP scintigraphy — confirmed with SPECT imaging — in the absence of any detectable monoclonal protein yields a specificity for ATTR cardiomyopathy approaching 100%. This transformed the field. Before this, confirming ATTR required endomyocardial biopsy, a procedure with real procedural risk that was not available at most centers and was not performed on patients who had not already been seriously suspected of the diagnosis. After Gillmore et al., any cardiologist with access to a nuclear medicine department could confirm ATTR-CM in a patient with LVH and HFpEF without a biopsy — provided they first excluded AL with serum markers, which is the non-negotiable prerequisite. The misuse of nuclear scintigraphy in patients with undiagnosed monoclonal protein leads to false-positive AL amyloidosis patients being labeled and treated as ATTR — a diagnostic and therapeutic error with serious consequences.
What the nuclear scan cannot tell you is whether the ATTR is wild-type or hereditary — that requires genetic testing. And that distinction matters enormously at a population level. The V142I mutation is present in 3.4% of Black Americans, which means millions of people carry a mutation that causes a fatal cardiomyopathy for which a proven treatment exists, and the vast majority will be diagnosed with HFpEF and treated with medications that worsen their physiology. A study of hospitalized HFpEF patients at Johns Hopkins found that 14% had cardiac amyloidosis on endomyocardial biopsy — not the 1-2% that the "rare disease" framing implies.[3,4] The epidemiology has been clarified. The diagnostic tools exist. The treatment is available. The only remaining barrier is the cardiologist who does not ask the question.
441 patients with ATTR-CM randomized to tafamidis (80 mg or 20 mg) vs. placebo. Win ratio 1.70 for composite mortality/CV hospitalization. 30% mortality reduction. Established tafamidis as the first disease-modifying therapy proven to reduce mortality in any TTR amyloidosis.
Multicenter validation of the non-biopsy diagnostic algorithm for ATTR-CM: grade 2–3 Tc99m-PYP/DPD uptake confirmed with SPECT in the absence of monoclonal protein has specificity approaching 100% for ATTR cardiomyopathy. The paper that replaced endomyocardial biopsy as the diagnostic standard for most ATTR-CM cases.
Daratumumab + CyBorD vs. CyBorD alone in newly diagnosed AL amyloidosis. Complete hematologic response 53.3% vs 18.1%; cardiac response 41.5% vs 22.2%. Established the daratumumab-containing regimen as the new standard of care for newly diagnosed AL amyloidosis.
American Heart Association Scientific Statement on evolving diagnosis and management of cardiac amyloidosis. Covers clinical presentation, diagnostic algorithms, staging, and therapeutic strategies across ATTR and AL subtypes. The most comprehensive clinical guidance document for practicing cardiologists.
[1] Gertz MA, Narula J, Argulian E, Mitter SS. Chapter 43: Cardiac Amyloidosis — Updated April 2023. In: Fuster V, Narula J, Vaishnava P, Leon MB, Callans DJ, Rumsfeld A, Poppas A, eds. Fuster and Hurst's The Heart, 15th ed. McGraw Hill, 2022.
[2] Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement from the American Heart Association. Circulation. 2020;142(1):e7–e22. PMID: 32476490. [PubMed]
[3] Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-Type Transthyretin Amyloidosis as a Cause of Heart Failure with Preserved Ejection Fraction. Eur Heart J. 2015;36(38):2585–2594. PMID: 26224076. [PubMed]
[4] Hahn VS, Yanek LR, Vaishnav J, et al. Endomyocardial Biopsy Characterization of Heart Failure with Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis. JACC Heart Fail. 2020;8(9):712–724. PMID: 32653448. [PubMed]
[5] Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(22):2872–2891. PMID: 31171094. [PubMed]
[6] Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404–2412. PMID: 27143678. [PubMed]
[7] Phelan D, Collier P, Thavendiranathan P, et al. Relative Apical Sparing of Longitudinal Strain Using Two-Dimensional Speckle-Tracking Echocardiography is Both Sensitive and Specific for the Diagnosis of Cardiac Amyloidosis. Heart. 2012;98(19):1442–1448. PMID: 22865865. [PubMed]
[8] Istrail L. The POCUS Textbook: Learn Point-of-Care Ultrasound of the Blood Vessels, Heart, & Lungs. ZeroGray Publishing, 2025. ISBN: 979-8-218-68730-4. [Buy on Amazon] Chapters 13 (Cardiac Views), 14 (Estimating Left Ventricular Ejection Fraction), 15 (Volume Overload and Venous Congestion).
[9] Maurer MS, Schwartz JH, Gundapaneni B, et al. (ATTR-ACT Study Investigators). Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016. PMID: 30145929. [PubMed]
[10] Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. (APOLLO Study Investigators). Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):11–21. PMID: 29972753. [PubMed]
[11] Kastritis E, Palladini G, Minnema MC, et al. (ANDROMEDA Study Investigators). Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med. 2021;385(1):46–58. PMID: 34192431. [PubMed]
[12] Solomon SD, Adams D, Kristen A, et al. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients with Hereditary Transthyretin-Mediated Amyloidosis. Circulation. 2019;139(4):431–443. PMID: 30586695. [PubMed]